指南与共识慢阻肺哮喘

α1-抗胰蛋白酶缺乏症靶向检测与增强治疗:加拿大胸科协会荟萃分析与临床实践指南

Alpha-1-Antitrypsin Deficiency Targeted Testing and Augmentation Therapy: A Canadian Thoracic Society Meta-Analysis and Clinical Practice Guideline.
指南 / 共识 · Chest · 2025-01-27

该指南由加拿大胸科协会制定,基于系统综述和荟萃分析,条件性推荐对COPD、成人起病哮喘伴持续气道阻塞及不明原因支气管扩张者检测A1AT缺乏;高临床怀疑者首选SERPINA1基因测序,中怀疑者先测血清A1AT水平;对特定基因型且A1AT严重降低的COPD患者条件性推荐增强治疗。

要点

  • 所有COPD患者在诊断时条件性推荐检测A1AT缺乏。
  • 高临床怀疑者首选SERPINA1基因测序,中怀疑者先测血清A1AT水平。
  • A1AT严重降低且符合条件的不吸烟或既往吸烟COPD患者可考虑增强治疗。

核心结论

  • 条件性推荐对COPD、成人起病哮喘伴持续气道阻塞及不明原因支气管扩张者进行A1AT缺乏检测。
  • 条件性推荐对符合特定基因型且A1AT水平严重降低的COPD患者使用A1AT增强治疗。

研究设计与样本

  • 加拿大胸科协会基于系统综述和荟萃分析,结合专家临床意见制定本临床实践指南。

主要发现

  • 许多严重A1AT缺乏者未确诊或诊断延迟,未能获得疾病特异性咨询和改善预后的治疗。
  • 自2012年加拿大胸科协会指南发布后,出现了采用现代基因检测优化诊断的新方法及A1AT增强治疗的研究。

关键数值与推荐

  • 高临床怀疑A1AT缺乏者,建议以SERPINA1基因DNA测序作为初始检测。
  • 中临床怀疑A1AT缺乏者,建议初始检测血清A1AT水平,若<23 μmol/L(<1.2 g/L)则进行SERPINA1基因DNA测序。
  • 发现A1AT基因异常(杂合子或纯合子)者,建议其一级亲属接受遗传咨询和A1AT缺乏检测。
  • 条件性推荐对不吸烟或既往吸烟的COPD患者(FEV1<80%预计值,伴肺气肿)、有明确缺乏基因型且A1AT水平严重降低(<11 μmol/L或<0.57 g/L)者,在最佳药物和非药物治疗基础上加用A1AT增强治疗。

临床怎么用

  • 对COPD、成人起病哮喘伴持续气道阻塞及不明原因支气管扩张者应检测A1AT缺乏。
  • 根据临床怀疑程度选择初始检测策略:高怀疑先基因测序,中怀疑先测血清A1AT水平。
  • 确诊基因异常者应为其一级亲属提供遗传咨询和检测。
  • 符合条件的COPD患者可在最佳治疗基础上考虑A1AT增强治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Alpha-1-antitrypsin (A1AT) deficiency is a common hereditary disorder associated with increased risk of developing chronic obstructive pulmonary disease (COPD). Many individuals with severe A1AT deficiency go undiagnosed, or are diagnosed late, and fail to benefit from disease-specific counseling and modifying care. Since the 2012 Canadian Thoracic Society (CTS) A1AT deficiency clinical practice guideline, new approaches to optimal diagnosis using modern genetic testing and studies of A1AT augmentation therapy have been published. We performed a systematic review and meta-analysis, which along with expert clinical input, informed recommendations. We conditionally recommend testing for A1AT deficiency in all individuals with COPD at the time of diagnosis, individuals with adult-onset asthma with persistent airway obstruction, and individuals with unexplained bronchiectasis. We suggest genetic testing with DNA sequencing of SERPINA1 gene as the initial test for individuals with high clinical suspicion for A1AT deficiency, and initial measurement of serum A1AT levels in individuals with moderate clinical suspicion of A1AT deficiency, followed by genetic testing with DNA sequencing of SERPINA1 gene if A1AT level is <23 μmol/L (<1.2 g/L). Following identification of an abnormal gene for A1AT in individuals, whether heterozygote or homozygote, we suggest first-degree relatives be provided genetic counseling and offered testing for A1AT deficiency. The panel conditionally recommends A1AT augmentation therapy to patients who do not smoke or who formerly smoked with COPD (forced expiratory volume in 1 s [FEV1] < 80% predicted; associated with emphysema), with documented deficiency genotypes and severely reduced A1AT level (< 11 μmol/L or < 0.57 g/L) in addition to receiving optimal pharmacological and nonpharmacological therapies for COPD.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Hernandez, Bossé, Bush, et al. Alpha-1-Antitrypsin Deficiency Targeted Testing and Augmentation Therapy: A Canadian Thoracic Society Meta-Analysis and Clinical Practice Guideline. Chest. 2025. PMID: 39880301. doi:10.1016/j.chest.2024.08.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。